Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Club foot / Talipes equinovarus

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15651
R64628
Blotière (Indications other than epilepsy), 2019 Talipes equinovarus 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.14 [0.16;8.12] C 1/980   1,677/1,875,733 1,678 980
ref
S17865
R75479
Eros (Indications NOS), 2002 Clubfoot during pregnancy (anytime or not specified) excluded case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched no data
excluded (exposition period)
0/-   -/- - -
ref
Total 1 studies 1.14 [0.16;8.12] 1,678 980
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Indications other than epilepsy), 2019Blotière, 2019 1 1.14[0.16; 8.12]1,6789800%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate0.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.14[0.16; 8.12]1,678980 -NABlotière (Indications other than epilepsy), 2019 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.14[0.16; 8.12]1,678980 -NABlotière (Indications other than epilepsy), 2019 1 Tags Adjustment   - No  - No 1.14[0.16; 8.12]1,678980 -NABlotière (Indications other than epilepsy), 2019 1 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.14[0.16; 8.12]1,678980 -NABlotière (Indications other than epilepsy), 2019 1 All studiesAll studies 1.14[0.16; 8.12]1,678980 -NABlotière (Indications other than epilepsy), 2019 10.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.14[0.16; 8.12]1,678980 -NABlotière (Indications other than epilepsy), 2019 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (Clonazepam) (All indication ...Veroniki a (NMA) (Clonazepam) (All indications) (Club foot) 4.03[0.46; 27.55]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.14[0.16; 8.12]NaN%980----Blotière (Indications other than epilepsy), 2019 10.510.01.0